The story of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated substantial gains, the lapse of its intellectual property protection opened the door to https://mnobookmarks.com/story21547376/sildenafil-and-the-pharmaceutical-industry-a-risky-bet